The role of βIII-tubulin in non-small cell lung cancer patients treated by taxane-based chemotherapy
详细信息 查看全文
- 作者：Kyoichi Kaira (1)
Toshiaki Takahashi (1)
Haruyasu Murakami (1)
Takehito Shukuya (1)
Hirotsugu Kenmotsu (1)
Akira Ono (1)
Tateaki Naito (1)
Asuka Tsuya (1)
Yukiko Nakamura (1)
Masahiro Endo (3)
Haruhiko Kondo (2)
Takashi Nakajima (4)
Nobuyuki Yamamoto (1) - 关键词：Class III β ; tubulin ; Taxane ; Chemotherapy ; NSCLC ; Chemoresistance ; Prognosis
- 刊名：International Journal of Clinical Oncology
- 出版年：2013
- 出版时间：June 2013
- 年：2013
- 卷：18
- 期：3
- 页码：371-379
- 全文大小：375KB
- 参考文献：1. Kawaguchi T, Takada M, Kubo A et al (2010) Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer. A comprehensive analysis of 26,957 patients with NSCLC. J Thorac Oncol 5:620-30
2. Kaira K, Yamamoto N (2010) Prognostic and predictive factors in resected non-small cell lung cancer. Expert Opin Med Diagn 4:1- CrossRef
3. Jordan MA, Wilson L (2001) Microtubules as a target for anticancer drugs. Nat Rev Cancer 4:253-65 CrossRef
4. Kang CH, Jang BG, Kim DW et al (2010) The prognostic significance of ERCC1, XRCC1, and β III-tubulin expression in patients with non-small cell lung cancer treated by platinum- and taxane-based neoadjuvant chemotherapy and surgical resection. Lung Cancer 68:478-83 CrossRef
5. Seve P, Reiman T, Dumontet C (2010) The role of βIII-tubulin in predicting chemoresistance in non-small cell lung cancer. Lung Cancer 67:136-43
6. Azuma K, Sasada K, Kawahara A et al (2009) Expression of ERCC1 and class III β-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel. Lung Cancer 64:326-33 CrossRef
7. Rosell R, Scagliotti G, Danenberg KD et al (2003) Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small cell lung cancer. Oncogene 22:3548-552 CrossRef
8. Dumontet C, Isaac S, Souquet PJ et al (2005) Expression of class III beta tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy. Bull Cancer 92:E25–E30
9. Seve P, Issac S, Tredan O et al (2005) Expression of class III β-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy. Clin Cancer Res 11:5481-486 CrossRef
10. Seve P, Mackey J, Issac S et al (2005) Class III β-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol Cancer Ther 4:2001-007 CrossRef
11. Hayashi Y, Kuriyama H, Umezu H et al (2009) Class III β-tubulin expression in tumor cells is correlated with resistance to docetaxel in patients with completely resected non-small-cell lung cancer. Intern Med 48:203-08 CrossRef
12. Volker M, Mone MJ, Kamakar P et al (2001) Sequential assembly of the nucleotide excision repair factors in vivo. Mol Cell 8:213-24 CrossRef
13. Simon GR, Sharma S, Cantor A et al (2005) ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest 127:978-83 CrossRef
14. Olaussen KA, Dunant A, Fouret P et al (2006) DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355:983-91 CrossRef
15. Zheng Z, Chen T, Li X et al (2007) DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 356:800-08 CrossRef
16. Mountain CF (1997) Revision in the International System for Staging Lung Cancer. Chest 11:1710-717 CrossRef
17. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-16 CrossRef
18. Koh Y, Jang B, Han SW et al (2010) Expression of class III beta-tubulin correlates with unfavorable survival outcome in patients with resected non-small cell lung cancer. J Thorac Oncol 5:320-25 CrossRef
19. Skov BG, Holm B, Erreboe A et al (2010) ERCC1 and Ki67 in small cell lung carcinoma and other neuroendocrine tumors of the lung: distribution and impact on survival. J Thorac Oncol 5:453-59 CrossRef
20. Kaira K, Endo M, Abe M et al (2010) Biologic correlation of 2-[18F]-fluoro-2-deoxy-d -glucose uptake on positron emission tomography in thymic epithelial tumors. J Clin Oncol 28:3746-753 CrossRef
21. Kaira K, Oriuchi N, Shimizu K et al (2008) Evaluation of thoracic tumors with 18F-FMT and 18F-FDG PET-CT: a clinicopathological study. Int J Cancer 124:1152-160 CrossRef
22. Kaira K, Oriuchi N, Imai H et al (2008) Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I-III nonsmall cell lung cancer. Br J Cancer 98:742-48 CrossRef
23. Davies AM, Lara PN Jr, Mack PC et al (2003) Docetaxel in non-small cell lung cancer: a review. Expert Opin Pharmacother 4:553-65 CrossRef
24. Maio MD, Chiodini P, Georgoulias V et al (2009) Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 27:1836-843 CrossRef
25. Azuma K, Komohara Y, Sasada T et al (2007) Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer Sci 98:1336-343 CrossRef
26. Vilmar A, Santoni-Rugiu E, S?rensen JB (2010) ERCC1, toxicity and quality of life in advanced NSCLC patients randomized in a large multicentre phase III trial. Eur J Cancer 13:1554-562 CrossRef
27. Sekine I, Nokihara H, Yamamoto N et al (2009) Comparative chemotherapeutic efficacy in non-small cell lung cancer patients with postoperative recurrence and stage IV disease. J Thorac Oncol 4:518-21 CrossRef - 作者单位：Kyoichi Kaira (1)
Toshiaki Takahashi (1)
Haruyasu Murakami (1)
Takehito Shukuya (1)
Hirotsugu Kenmotsu (1)
Akira Ono (1)
Tateaki Naito (1)
Asuka Tsuya (1)
Yukiko Nakamura (1)
Masahiro Endo (3)
Haruhiko Kondo (2)
Takashi Nakajima (4)
Nobuyuki Yamamoto (1)
1. Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan
3. Division of Diagnostic Radiology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan
2. Division of Thoracic Surgery, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan
4. Division of Diagnostic Pathology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan - ISSN：1437-7772
文摘
Background The aim of this study is to evaluate whether class III β-tubulin (TUBB3) expression could predict progression-free survival or overall survival in relapsed non-small cell lung cancer (NSCLC) patients treated with taxene-based chemotherapy. Methods Immunohistochemistal staining was used to examine the expression of TUBB3 in resected lung tumor specimens obtained from 56 patients treated with platinum-based chemotherapy against recurrent tumors after curative resections. Excision repair cross-complementation group 1, breast cancer susceptibility gene 1, vascular endothelial growth factor, Ki-67, CD34, and p53 were also correlated with clinical features and outcome after treatment. Results Of the 56 patients enrolled in the study, 29 were treated by carboplatin plus paclitaxel as first-line treatment, and 24 patients received docetaxel monotherapy as second- or third-line treatment. A positive TUBB3 expression is closely associated with a poor response to taxane-based chemotherapy. TUBB3 expression was an independent prognostic factor for predicting poor progression-free survival after docetaxel administration. However, TUBB3 expression could not predict outcome after carboplatin plus paclitaxel treatment. The other biomarkers tested were not independent prognostic factors for predicting outcome after taxane-based chemotherapy. Conclusion TUBB3 expression is associated with resistance to taxane-based chemotherapy and is an independent prognostic factor for predicting poor progression-free survival after docetaxel treatment alone. TUBB3 expression may be a predictive marker for chemoresistance to docetaxel in NSCLC with postoperative recurrent disease.